Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Tesofensine cycle length: what human studies ran

InvestigationalBLimited human data
Short answer: there is no established Tesofensine cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. Obesity phase 2: 24 weeks; neurology phase 2: 14 weeks 1,4.
  2. Tesomet in hypothalamic obesity: 24 weeks 6.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Tesofensine combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Tesofensine cycle length?
No. Human studies administered Tesofensine for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Tesofensine?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Tesofensine dosing reference Full research page

References

  1. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial Lancet. 2008
  2. Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial Lancet. 2013
  3. Under-reporting of adverse effects of tesofensine Lancet. 2013
  4. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease Obesity (Silver Spring). 2008
  5. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study Arch Neurol. 2008
  6. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity Eur J Endocrinol. 2022
  7. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users Clin Pharmacol Ther. 2010
  8. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease Br J Clin Pharmacol. 2007
  9. Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus (NCT02737891), registry record with posted results ClinicalTrials.gov. 2017
  10. Drugs@FDA application data queried through openFDA for tesofensine (no matching application record returned on 23 October 2026) openFDA / Drugs@FDA. 2026
  11. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories 1, 2 and 3; updated May 14, 2026) FDA. 2026
  12. PubChem compound record for tesofensine (CID 11370864; CAS 195875-84-4) PubChem. 2026
  13. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026